Dr. Paul Averback reports

NYMOX REPORTS COMPLETION OF $2 MILLION PRIVATE PLACEMENT

Nymox Pharmaceutical Corp. has completed its recently reported private placement of $2-million (U.S.). This new financing was undertaken for general corporate purposes and was priced at $1 (U.S.) per share. The investment was provided by long-term shareholder and distinguished Nymox board member James Robinson.

Dr. Paul Averback, chief executive officer of Nymox, said: "The company has a number of important initiatives under way that will benefit greatly from this timely support. We are looking forward to providing further positive updates and reports at the appropriate times."

About Nymox Pharmaceutical Corp.

Nymox is in the process of submitting applications for the approval to market the company's first-in-class drug, Nymozarfex, to treat the symptoms of benign prostatic hyperplasia (BPH). BPH is one of the most common conditions affecting middle-aged and elderly men throughout the world. BPH can be devastating to men who suffer from the condition. Current treatments are associated with numerous intolerable side effects, including sexual problems, such as impotence and retrograde ejaculation. Medications for BPH have been associated with prostate cancer, depression, gynecomastia and other adverse effects. The majority of men stop taking the available medications due to these and other problems. Surgery is often needed for advanced BPH. Surgery is usually effective but it is not without risks and the discomforts of surgery, and BPH surgery has side effects such as permanent retrograde ejaculation for many patients.

Nymox recently reported 10-year follow-up new data on all available patients from its U.S. clinical trial of Nymozarfex for the treatment of low-grade localized prostate cancer. The available long-term data newly assessed confirmed that all available data show that the Nymozarfex treatment had important and statistically significant benefit for reducing the long-term progression of these prostate cancers.

About Nymozarfex (fexapotide)

Nymozarfex is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving over all more than 1,750 patients with over 1,600 injections administered, including over 1,200 Nymozarfex administrations. Nymozarfex has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.

We seek Safe Harbor.